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SUMMARY
Advanced stage papillary serous tumors of the ovary are responsible for the majority of ovarian cancer
deaths, yet the molecular determinants modulating patient survival are poorly characterized. Here, we iden-
tify and validate a prognostic gene expression signature correlatingwith survival in a series ofmicrodissected
serous ovarian tumors. Independent evaluation confirmed the association of a prognostic gene microfibril-
associated glycoprotein 2 (MAGP2) with poor prognosis, whereas in vitro mechanistic analyses demon-
strated its ability to prolong tumor cell survival and stimulate endothelial cell motility and survival via the
aVb3 integrin receptor. IncreasedMAGP2expression correlatedwithmicrovessel density suggesting aproan-
giogenic role in vivo. Thus, MAGP2 may serve as a survival-associated target.INTRODUCTION
Ovarian cancer is the fifth most common form of cancer in
women in the United States, accounting for 3% of the total
number of cancer cases and for 26% of those cases occurring
in the female genital tract. Epithelial ovarian cancer is highly
lethal. In 2009, there will be an estimated 21,550 new cases
and 14,660 deaths from ovarian caner in the United StatesCa(Jemal et al., 2009). Of these deaths, the vast majority will be
attributed to papillary serous tumors, which account for 60%
of all cases (Boring et al., 1994). Most of these tumors are de-
tected at an advanced stage with metastases present beyond
the ovaries precluding curative treatment (Boente et al., 1996).
Clinical management of this disease involves tumor debulking
followed by administration of carboplatin chemotherapy.
Despite the fact that 80% of advanced ovarian cancers (stagesSIGNIFICANCE
Ovarian cancer is the most lethal gynecologic cancer in the United States, yet little is known about the molecular events
impacting survival. Thus, efforts to stratify patients for therapy and identify therapeutic targets have been severely
hampered. We have now identified and confirmed a gene expression signature correlating with poor survival in microdis-
sected advanced serous ovarian tumors. In addition, we have completed an initial characterization of a proangiogenic factor
associated with prognosis, MAGP2, which can promote tumor epithelial cell survival and stimulate endothelial cell motility
and survival. Correlation of MAGP2 with microvessel density suggests a role in neovascularization in vivo. This work has
developed a prognostic gene signature of biological significance and identified a putative ovarian cancer target.ncer Cell 16, 521–532, December 8, 2009 ª2009 Elsevier Inc. 521
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Prognostic Gene Signature in Serous Ovarian CancerFigure 1. Identification and Validation of a Prognostic Gene Expression Signature Correlating with Survival in 53 Microdissected Late-Stage
High-Grade Papillary Serous Ovarian Tumors
(A) Hierarchical clustering of 53 advanced stage, high-grade serous adenocarcinomas using expression values for genes possessing a Cox score >10
(gene expression: red, upregulated; blue, downregulated; survival: blue, short survival; red, long survival).
(B) Genes presented in this table possessed a large Cox score (>10). Only the probe set with the highest Cox score is presented for MAGP2.
(C) Kaplan Meier analysis of the predictor demonstrated a significant difference in survival time (p = 0.0029).
(D) Kaplan Meier survival analysis of 49 patients using qRT-PCR validation data obtained for the top 11 survival-signature genes confirmed the two groups
retained significantly different survival endpoints (p = 0.0107).III and IV) respond to primary treatment with surgery and chemo-
therapy, the disease usually recurs and is ultimately fatal. A
subset of these patients will develop a more chronic form of
ovarian cancer and may survive 5 years or more with treatment.
Consequently, there is a pressing need for diagnostic classifiers
that can reliably stratify patients for therapy, as well as targets for
therapeutic intervention.
Previous studies have shown that large-scale transcription
profiling can identify differentially expressed genes and molecular
signatures in numerous biological systems including ovarian
cancer (Alizadeh et al., 2000; Bonome et al., 2005; DeRisi et al.,
1997; Golub et al., 1999). More recent efforts to derive clinical
predictors for survival in ovarian cancer from gene expression
data have focused on discrete patient groups clustered at either
end of the survival spectrum (Berchuck et al., 2005; Lancaster
et al., 2004). Yet, expression patterns identified in this manner
may not adequately differentiate the majority of patients who
will succumb at an intermediate endpoint. In addition, the evalu-
ation of undissected tumor isolates may introduce erroneous data
attributable to varying amounts of intervening stroma and
lymphocytic infiltrate. In this study, we describe the use of
a whole-genome oligonucleotide array to perform expression
profiling on a series of microdissected late-stage, high-grade
papillaryserousovarianadenocarcinomas to identifyaprognostic
gene signature correlating with survival as a continuous variable.522 Cancer Cell 16, 521–532, December 8, 2009 ª2009 Elsevier Inc.RESULTS
Derivation and Validation of a Gene Signature Predictive
for Survival in Patients with Advanced Papillary Serous
Ovarian Cancer
We identified 53 advanced stage, high-grade primary tumor
specimens from patients with papillary serous adenocarcinomas
of the ovary whose survival spanned a spectrum of 145 months
(see Table S1, available online). The average age for the cohort
was 61.9 years (SD = 12.7), with an average survival time of
40.5 months following surgery (SD = 41.3 months). Among these
patients, 12 were still alive when we analyzed the data and
11 patients were suboptimally debulked. All specimens were
subjected to laser-based microdissection and analyzed as
pure, microdissected epithelial cell populations on whole-
genome Affymetrix U133 Plus 2.0 GeneChip microarrays.
To derive the predictor, we used a two-step ‘‘semi-super-
vised’’ approach using Cox regression analysis and leave-one-
out cross-validation to identify and validate the survival signa-
ture. The performance of the prediction analysis was visualized
by hierarchical clustering, which demonstrated the ability of
the top scoring genes (Cox hazard ratio >10) to cluster the 53
specimens according to survival (Figure 1A). As detailed in
Figure 1B, the gene possessing the highest hazard ratio was
MAGP2. Finally, the validity of the entire 200 probe set classifier
Cancer Cell
Prognostic Gene Signature in Serous Ovarian Cancer(see Table S2) was evaluated by a non-parametric log rank test
using median hazard to stratify the patients. The test was highly
significant, with the high-risk group, defined by predicted hazard
greater than median hazard, having a significantly shorter
survival than the low-risk group (Figure 1C). This result confirmed
that our model was able to predict a patient’s hazard accurately.
We also investigated other predictor compositions varying the
number (100 or 300) of probe sets and principal components
(PCs) (four or six) that were assessed and found our results
remained nearly identical (data not shown).
In order to validate the survival signature, the 11 genes pos-
sessing the highest Cox hazard ratios were selected. Quantita-
tive RT-PCR (qRT-PCR) was performed on all 53 RNA samples,
which were included in the microarray analysis, using primers
specific for each gene. Assayable expression levels for each
gene were obtained in 49/53 samples and used to generate a
Kaplan Meier plot in a fashion analogous to the microarray
analysis. A nonparametric log rank test showed the two groups
retained a significant survival difference (Figure 1D), confirming
the microarray data.
Identification of Signaling Events Affecting Patient
Survival
To ascertain whether subsets of the survival-associated genes
might be participating in coordinated signaling pathway(s)
contributing to patient outcome, we compared the 53 advanced
stage ovarian adenocarcinoma specimens to 10 normal ovarian
surface epithelium (OSE) brushings. A total of 5022 probe sets
were differentially regulated. Both differential gene expression
data and identifiers for the top 150 survival-associated probe
sets (Cox Hazard >8.5) were overlaid onto a biological associa-
tion network for identification of coregulated pathways.
Integrin-mediated signaling stimulated by MAGP2 engage-
ment of the aVb3 receptor featured prominently in the analysis
(Figure 2A). Although the receptor subunits were not differentially
regulated in the tumor specimens, a number of downstream
effectors were overexpressed versus OSE including PXN, FAK,
Figure 2. Assessment of Putative Signaling
Events Contributing to Patient Survival
(A)Pathway analysisofselectdifferentially regulated
genes identified in the 53 microdissected serous
tumors, as compared to 10 normal OSE brushings
(red, upregulated; blue, downregulated; gray, no
change; red halo, survival-associated gene).
(B) Heat map demonstrating association between
survival signature genes identified in the pathway
and overall patient survival. Increased expression
of one or more genes greatly reduced patient
survival.
(C) qRT-PCR validation of select genes identified
in the pathway analysis for all 53 tumor samples
and 10 normal OSE. Error bar represents mean
fold change ± SD.
GRB2, and SOS1. Contributing to this
pathway were a number of genes impli-
cated in patient survival including
MAGP2, FGF18, FGFR2, ADAM12,
NEDD9, MMP13, and CDC2. Of these,
MAGP2, FGF18, FGFR2, andCDC2 were also significantly upre-
gulated, when compared to normal OSE. A unique feature of
MAGP2, FGF18, and TNFAIP6 is their ability to modulate endo-
thelial cell behavior. The cognate receptors of each protein are
also expressed in tumor endothelial cells, suggesting that patient
survival may consist of signaling events specific to the trans-
formed cell, as well as induced endothelial cell changes. Further-
more, it is possible that pronounced expression of one or
more survival-associated genes may dramatically enhance the
aggressiveness of the disease negatively impacting patient
outcome (Figure 2B).
To substantiate the pathway analysis, we completed qRT-
PCR for five differentially regulated genes including MAGP2,
CCND1, FAK, STMN1, and DAB2 for all 53 tumor specimens,
as well as the ten normal OSE isolates. Student’s t test confirmed
all five genes were differentially regulated relative to normal OSE
at levels comparable to the array data (Figure 2C).
Characterization of Clinical Correlates Associated
with the Survival Signature Gene MAGP2
Although the probe sets identified in the analysis predict for
patient survival as a group, each gene was selected according
to its individual Cox hazard ratio. Thus, genes possessing a
high hazard ratio may independently predict for patient survival.
MAGP2 was identified by three separate probe sets and scored
the highest hazard ratio. In addition, pathway analysis suggested
it may participate in coregulated signaling events contributing to
enhanced tumor cell survival and prolonged endothelial cell
survival and motility distinguishing MAGP2 as a suitable candi-
date for further characterization.
To extend the analysis, we evaluated MAGP2 as an indepen-
dent prognostic factor. Comparative genome hybridization
(CGH) with a 20,000 element oligonucleotide microarray demon-
strated a median MAGP2 copy number approaching 2.5 in a
subset of the tumor specimens (Figure 3A). This observation
was supported by qPCR analysis correlating amplification of
the locus with CGH copy number (Figure 3B). qRT-PCR analysisCancer Cell 16, 521–532, December 8, 2009 ª2009 Elsevier Inc. 523
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MAGP2 mRNA expression and patient survival. Stratifying the
expression values according to the mean showed a significantly
shorter survival time for patients expressing MAGP2 mRNA
above the mean (Figure 3C). A significant correlation between
MAGP2 DNA and mRNA copy number was not observed, sug-
gesting that amplification may only be one of the mechanisms
leading to upregulation of MAGP2 in epithelial ovarian cancer
cells.
Immunolocalization of MAGP2 protein in all 53 optimally
debulked stage III grade 3 serous adenocarcinoma, as well as
normal ovarian epithelium and benign cysts, demonstrated
low-level expression of MAGP2 in normal ovarian epithelial cells
(Figure 3D, subpanel A) and benign cysts (Figure 3D, subpanel
C), but elevated levels in a proportion of malignant tumors
(Figure 3D, subpanels B and D). The intensity of MAGP2 staining
was analyzed with the survival data and examined by Kaplan
Figure 3. The MAGP2 Locus Is Amplified in
Serous Ovarian Tumors and Its Expression
Products Are Significantly Correlated with
Overall Survival and Chemoresponse
(A) Oligonucleotide microarray CGH for 42 of the
serous tumors established the median MAGP2
copy number (2.5) on chromosome 12p. MAGP2
is highlighted in red.
(B) qPCR correlated with the CGH microarray data
for 29 of the serous tumors (r = 0.61, p = 0.004).
(C) Kaplan Meier survival analysis of MAGP2
mRNA expression using the 53 patients with stage
III/IV high-grade serous ovarian cancer demon-
strated a significant difference in patient outcome
(p = 0.001).
(D) Low-level MAGP2 protein staining was
observed in normal surface epithelia (A), epithelial
and stromal components of benign ovarian cysts
(C), and in some high-grade serous tumors (B).
Strong MAGP2 staining was observed in a small
proportion of high-grade serous ovarian tumor
tissues (D). Arrowheads indicate the epithelial
layer of the normal ovary and benign ovarian cyst
(S, stroma; T, tumor cells).
(E) Kaplan Meier survival analysis of MAGP2
protein expression using 53 patients with stage
III/IV high-grade serous ovarian cancer. A statisti-
cally significant difference was observed between
the outcome groups (p = 0.05).
(F) Independent TMA validation of MAGP2 expres-
sion in 64 serous ovarian cancers. A, high-level
staining; B, moderate staining; C, low-level
staining.
(G) Box plot analysis of MAGP2 protein expression
levels among chemotherapy responders and non-
responders. A significant correlation was found
between poor response and increased MAGP2
protein levels (p = 0.018).
Meier survival analysis. The results indi-
cated that patients positive for MAGP2
possessed a poor prognosis (Figure 3E).
Independent validation of this association
was completed with a 64 element tissue
microarray (TMA) consisting of advanced
stage high-grade serous adenocarcinoma specimens (Figure 3F
and Table S1). MAGP2 staining intensity was correlated with
survival and adjusted for debulking status by multivariate Cox
regression analysis. A significant association was found between
the degree of MAGP2 staining and survival (hazard ratio: 1.857;
p = 0.004; 95% confidence interval [1.253 and 2.752]).
Resistance to chemotherapy has been linked to aVb3 signaling
in a number of tumor systems including ovarian cancer (Maubant
et al., 2002). Consequently, stimulation of the receptor by
MAGP2 may attenuate chemoresponse, ultimately affecting
patient survival. A subset (47) of the 64 tumors from the validation
set analyzed was evaluable for chemotherapeutic response
status. Tumors were stratified into two groups, resistant and
responsive to chemotherapy, as defined by objective evidence
of complete or partial remission. MAGP2 expression levels
were significantly lower in patients who responded to chemo-
therapy (Figure 3G).524 Cancer Cell 16, 521–532, December 8, 2009 ª2009 Elsevier Inc.
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Prognostic Gene Signature in Serous Ovarian CancerFigure 4. MAGP2 Is Expressed in Ovarian
Cancer Cells and Enhances Adhesion and
Survival In Vitro
(A) Western blot analysis of MAGP2 protein iso-
lated from 2 normal HOSE cultures and 12 ovarian
cancer cell lines.
(B) Flow cytometry analysis of aVb3 cell surface
receptor levels in select high and low MAGP2-
expressing cell lines using monoclonal antibodies
against aVb3 or IgG1 isotype control.
(C) Silver staining for total protein obtained from
yeast clone 10 supernatant identifies recMAGP2
as the principal secreted product following
purification.
(D) Increased adhesion of A224 ovarian cells in the
presence of purified recMAGP2 (p < 0.02), with
reduced adhesion following anti-aVb3 integrin
antibody treatment (p < 0.01).
(E) aVb3 integrin receptor-negative UCI107 cells
displayed no significant increase in adhesion in
the presence of recMAGP2.
(F) OVCA429 cell viability was evaluated with
increasing concentrations of recMAGP2. In-
creased cell survival was seen at higher concen-
trations of recMAGP2 reaching a maximum at
200 ng/ml (p = 0.004). For (E) and (F), data are
the mean ± SD of three independent experiments.
(G) Survival signaling in OVCA429 cells in re-
sponse to treatment with recMAGP2. Differentially
regulated genes were identified (red, upregulated;
blue, downregulated; gray, no change).Recombinant MAGP2 Stimulates Serous Ovarian
Cancer Cell Adhesion and Survival
To determine potential mechanisms by which MAGP2 negatively
impacts patient survival, we conducted in vitro assays on a panel
of serous ovarian cancer cell lines. Screening the panel for
MAGP2 expression by western blotting (Figure 4A), as well as
aVb3 receptor status through flow cytometry analysis (Figure 4B,
select cell lines only), facilitated the selection of cell lines
amenable to biological characterization. Among cell lines ex-
pressing MAGP2, only SKOV3 coexpressed the aVb3 receptor.
More importantly, two cell lines, A224 and OVCA429, were posi-
tive for aVb3, yet lacked measurable levels of MAGP2. These cell
lines were chosen for subsequent analyses involving the re-
combinant protein along with UCI107, which was negative for
both the receptor and MAGP2.
To test whether MAGP2 can modulate tumor cell biology, we
synthesized purified recombinant MAGP2 (recMAGP2) using a
yeast expression system (Figure 4C). Given that MAGP2 has
been shown to induce adhesion in a number of different cell
types via the aVb3 integrin receptor (Gibson et al., 1999), we
selected this endpoint to verify the biological activity of the
construct. The effect of recMAGP2 on cellular adhesion was
evaluated for A224 and UCI107 cell lines. When plated on
recMAGP2-coated wells, A224 cells displayed an increase in
adhesion (Figure 4D), relative to control wells. Preincubation of
A224 cells with anti-aVb3 integrin-blocking antibody resulted
in a decrease in adhesion on recMAGP2-coated wells (Fig-
ure 4D), whereas pretreatment with control IgG1 antibody had
no effect. In contrast, UCI107 showed no increase in adhesion
at high concentrations of recMAGP2, further demonstrating the
suitability of recMAGP2 for biological evaluation (Figure 4E).CBased on the pathway analysis, aVb3-mediated signaling
was implicated in ovarian tumor cell survival through the stim-
ulation of critical cell-cycle checkpoint regulators. To assess
this observation, we cultured OVCA429 cells under increasing
concentrations of purified recMAGP2. At 96 hr, a significant
difference in survival was observed for cells treated with
200 ng/ml of recMAGP2 in serum-free media (Figure 4F).
This observation substantiated the pathway, suggesting that
differential patient survival may be attributed in part to en-
hanced tumor cell survival through MAGP2-induced signaling
events.
RecMAGP2 Stimulates the Adhesion, Survival,
Migration, and Invasion of Human Umbilical
Vein Endothelial Cells
As indicated in Figure 2A, we hypothesized that secreted
MAGP2 may modulate the biology of surrounding endothelial
cells ultimately promoting neovascularization. aVb3 integrin is
expressed on endothelial cells and has been associated with
tumor angiogenesis (Ellis et al., 2003). To probe these biological
effects, we cultured human umbilical vein endothelial cells
(HUVECs) in the presence of recMAGP2.
As observed for A224 ovarian cancer cells, HUVECs plated
on recMAGP2 showed a 3.5-fold increase in cellular adhesion
(Figure 5A). This effect was blocked by pretreatment with an
anti-aVb3 integrin antibody, whereas control IgG1 antibody
had no effect (Figure 5A). This suggests that recMAGP2 also
exerts its biological activity through the aVb3 integrin receptor
in HUVECs. To determine the effect of recMAGP2 on survival,
HUVECs were grown under low serum conditions. Cells grown
in the absence of recMAGP2 for 5 days displayed a reductionancer Cell 16, 521–532, December 8, 2009 ª2009 Elsevier Inc. 525
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Prognostic Gene Signature in Serous Ovarian CancerFigure 5. RecMAGP2 Stimulates Adhesion,
Survival, Motility, and Invasion of HUVECs
In Vitro
(A) HUVECs cultured on recMAGP2 showed
increased adhesion (p < 0.0002) when compared
to anti-aVb3 integrin antibody preincubation.
(B) Enhanced survival of HUVECs treated with
recMAGP2 (p < 0.05).
(C) Dose-dependent HUVEC motility in response
to recMAGP2 protein was significant at all concen-
trations evaluated (p% 0.01).
(D) Anti-aVb3 integrin antibody attenuated re-
cMAGP2-stimulated HUVEC motility through
aVb3 receptor inhibition (p < 0.002), whereas anti-
a5 and anti-b1 integrin antibody treatments did not.
(E) Successful processing and secretion of wild-
type supMAGP2 and RGD motif mutant proteins
by 293T cells (1, signal sequence; 2, RGD motif;
3, N-linked carbohydrate consensus sequence;
the underlined letter refers to the mutated RGD
motif amino acid).
(F) supMAGP2 stimulated HUVEC motility (p =
0.002), whereas the three mutant constructs had
no significant effect.
(G) Proper processing and secretion of wild-type
OVsupMAGP2 protein by UCI107 ovarian cancer
cells.
(H) Ovarian cancer cell-derived OVsupMAGP2
induced HUVEC motility (p < 0.001).
(I) Increased invasion of recMAGP2-treated HU-
VECs into matrigel, as compared to untreated cells
(p < 0.05). For (A)–(D), (F), (H), and (I), the data
represents the mean ± SD of three independent
experiments.(25%) in survival, which was partially restored in the presence of
recombinant protein (Figure 5B).
The effect of recMAGP2 on HUVEC motility and invasion
was also evaluated. Application of recMAGP2 increased cell
motility in a dose-dependent manner, as compared with cells
incubated with medium alone, for all of the concentrations
evaluated (Figure 5C). The addition of anti-aVb3 antibody in
the presence of recMAGP2 attenuated cell motility (Figure 5D).
Given that other integrin protein family members also possess
the ability to bind proteins that possess an RGD motif,
including the a5 and b1 receptors, their contribution to re-
cMAGP2-induced motility was determined (Takada et al.,
2007). Relative to IgG1, neither anti-a5 nor anti-b1 antibodies
had a significant impact on recMAGP2-stimulated HUVEC
motility, suggesting that signaling is specific to the aVb3
receptor (Figure 5D). To confirm that the RGD motif of
MAGP2 is required for its biological activity, we evaluated
supernatants containing secreted MAGP2 (supMAGP2) from
293T cells transfected with wild-type MAGP2 or one of three
RGD motif mutant constructs (Figure 5E). Only wild-type
supernatant stimulated HUVEC migration (Figure 5F). Finally,
wild-type MAGP2 was transfected into ovarian cancer cell
line UCI107, which does not express MAGP2, so that the
ability of an ovarian tumor cell to successfully process and
secrete functional protein could be verified (Figure 5G). Appli-
cation of MAGP2-enriched tumor cell-derived supernatant
(OVsupMAGP2) induced HUVEC motility compared to the
vector control (Figure 5H).526 Cancer Cell 16, 521–532, December 8, 2009 ª2009 Elsevier IncIn addition to survival and motility, exposing HUVECs seeded
onto Matrigel matrix to reMAGP2 stimulated a 2-fold increase in
invasion (Figure 5I). Summation of these results implicates the
RGD motif of MAGP2 as a potent modulator of endothelial cell
behavior acting through the aVb3 receptor, which may contribute
to angiogenesis, affecting patient survival.
Identification of Signaling Events Contributing
to the Effect of Recombinant MAGP2 on HUVECs
The marked effect of recMAGP2 on HUVEC behavior implied
a change in cellular regulation had taken place, affecting gene
expression (Figure 6A). To explore the consequences of
recMAGP2-induced signaling, we completed microarrays for a
series of recMAGP2-treated (n = 3) and untreated (n = 3) HUVEC
isolates. A total of 274 probe sets were identified for pathway
analysis in cells exposed to recMAGP2 (Figure 6B). Among
them were ITGAV, FAK, and CDC42, suggesting that MAGP2-
stimulated signaling may induce the expression of key effectors
enhancing its activity in HUVECs. In addition, a number of genes
involved in the formation of endothelial cell tight junctions
including CLDN5, PKD1, and JAM3 were downregulated,
whereas motility genes CDC42 and APC were upregulated.
Deregulation of these genes may lead to a reduction in vessel
integrity, permitting endothelial cell migration and neovasculari-
zation.
Given that FAK is a critical mediator of aVb3 signaling, we
confirmed its phosphorylation status in recMAGP2-treated cells.
With a phosphorylation-specific antibody recognizing tyrosine.
Cancer Cell
Prognostic Gene Signature in Serous Ovarian CancerFigure 6. Identification of Putative
Signaling Events Mediating the Effects of
MAGP2 on HUVECs
(A) Hierarchical clustering of recMAGP2-treated
(n = 3) and untreated (n = 3) HUVECs following
supervised class comparison. The top 50 differen-
tially regulated probe sets are displayed (red,
upregulated; blue, downregulated).
(B) Signaling events stimulated in HUVECs treated
with recMAGP2 as compared to untreated cells.
Differentially regulated genes were identified
(red, upregulated; blue, downregulated; gray, no
change).
(C) recMAGP2 treatment of HUVECs increased the
proportion of phosphorylated FAK, as compared
to untreated cells. Error bar represents the area/
second mean ± SD of three independent experi-
ments.
(D) Time course changes in [Ca2+] levels in a single
recMAGP2 induced in a single HUVEC.
(E) Mean normalized time course changes in [Ca2+]
induced by recMAGP2 in HUVECs.
(F) Mean normalized time course of changes in
[Ca2+] induced by recMAGP2 in HUVECs pre-
treated with GRGDSP competitor peptide.397, a western blot comparing phospho-FAK to total FAK was
completed for both treated and untreated HUVEC isolates
(Figure 6C). In cells treated with the recombinant protein, there
was a 2-fold increase in phosphorylated FAK, indicating elevated
levels of activated protein, whereas no change was seen in
untreated cells. Furthermore, treatment of UCI107 ovarian
cancer cells, which are null for aVb3, and HUVEC cells in the pres-
ence of blocking antibody to aVb3 with recMAGP2 resulted in no
activation of FAK (Figure S1).
In order to identify the mechanism underlying the stimulation
of FAK by recMAGP2, we assessed Ca2+ oscillation in treated
HUVECs. Ca2+ mobilization and oscillation has been associated
with the activation of FAK in motile cells (Giannone et al., 2004).
recMAGP2 induced an immediate increase in [Ca2+]I levels
(Figures 6D and 6E). When cells were pretreated with a synthetic
RGD peptide, the effect of recMAGP2 on [Ca2+]I levels was
severely diminished (Figure 6F). Furthermore, the addition of
BAPTA/AM to HUVEC cells treated with recMAGP2 inhibits
the activation of FAK (Figure S2). These data imply that
FAK is activated through Ca2+ mobilization in response to
recMAGP2 in HUVECs. This may account in part for the
enhanced motility and survival of HUVECs described in the
pathway analysis.
In parallel with these experiments, we sought to determine the
mechanism(s) of MAGP2-induced survival of ovarian cancer
cells. To explore the consequences of recMAGP2-induced
survival, we completed microarrays for a series of recMAGP2-
treated (n = 3) and untreated (n = 3) OVCA429 cells. A total of
389 probe sets were identified as differentially expressed under
recMAGP2 treatment (Table S3). As one might expect, there was
overlap between this gene list and that obtained by exposure
of HUVEC cells to recMAGP2. A pathway was identified that
again centered on fak but included other important survival-
related genes such as cflar (Figure 4G). Cflar is upregulated by
recMAGP2 and in turn this gene inhibits and regulates multiple
important mediators of apoptosis.CMAGP2 Expression Is Necessary for In Vivo
Tumor Size Growth
To investigate the effects of decreased MAGP2 expression on
ovarian tumor growth and microvessel density in vivo, we
‘‘knocked down’’ MAGP2 expression in SKOV3 clones by stably
transfecting the cells with MAGP2 shRNA (Figure 7A). Four
clones with decreased MAGP2 along with two vector control
clones were injected into nude mice. After tumor development,
the animals were sacrificed and tumors were removed and
weighed. Tumors with reduced levels of MAGP2 were signifi-
cantly smaller than those that developed from control cells
(Figure 7B). To validate these results, we used lentiviral particles
expressing shRNA to knock down MAGP2 expression in both
SKOV3 and OVCAR3 cell lines. Pools of clones were isolated,
each pool expressing a MAGP2 shRNA targeting a different
region of the MAGP2 gene sequence. Reduced expression of
MAGP2 was seen for all pools compared with controls (nontar-
geting shRNA) and this resulted in decreased tumor size
(Figure S3).
Microvessel density in the tumors was measured by immuno-
localization of CD34+. A decrease in MAGP2 expression
resulted in decreased CD34+ microvessel density (Figure 7C). It
is important to note that these ovarian tumors express MAGP2
specifically in the tumor epithelial cells and not the stromal or
endothelial cells (Figure 7D).
MAGP2 Expression Is Significantly Correlated
with CD34 Expression in Serous Ovarian Cancer
Given the pronounced biologic effect of MAGP2 on endothelial
cells, we hypothesized that tumors with elevated MAGP2
expression would display features indicative of a proangiogenic
microenvironment. To evaluate whether MAGP2 may induce
angiogenesis in ovarian tumors, MAGP2 expression was corre-
lated with microvessel density in 30 human advanced serous
cancers. MAGP2 expression was determined by immunolocali-
zation of the MAGP2 protein with an anti-MAGP2 polyclonalancer Cell 16, 521–532, December 8, 2009 ª2009 Elsevier Inc. 527
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immunolocalization of CD34+ microvasculature within the tissue
with an anti-CD34 monoclonal antibody (Figures 7E and 7G). A
significant correlation between MAGP2 expression and CD34+
microvessel density was detected (Figure 7F, p = 0.009). These
data suggest that MAGP2 may play a role in ovarian tumor
neovascularization in vivo.
DISCUSSION
Patients suffering from advanced stage ovarian cancer often
display a heterogeneous clinical course with overall survival
spanning less than 5 months to beyond 150. The development
of genomic classifiers will aid in the clinical management of the
disease, as well as identify new opportunities for therapeutic
intervention. The work reported here describes a validated
gene expression signature correlating with survival in patients
with advanced serous ovarian cancer. To biologically validate
the signature, we have characterized the gene possessing the
highest Cox score, a secreted factor, MAGP2, and demon-
strated that the protein promotes ovarian tumor cell survival as
well as endothelial cell survival, motility, and invasion. Further-
more, expression of MAGP2 correlates with microvessel density
in ovarian cancer.
Transcription profiling is widely used to derive molecular
signatures associated with ovarian cancer (Bonome et al.,
Figure 7. MAGP2 Expression Correlates
with Tumor Size and CD34+ Microvessel
Density in Serous Ovarian Cancer Tumors
and Tissue Specimens
(A) Western blot demonstrated knockdown of
MAGP2 in five clones isolated from stably trans-
fected SKOV3 cells, as well as three empty vector
clones.
(B) MAGP2 knockdown resulted in significantly
decreased tumor size in mice. The median weight
of tumors from SKOV3 cells is 0.18 g; knockdown
of MAGP2 results in a significant decrease in
tumor weight (0.02 g; p < 0.01).
(C) MAGP2 knockdown resulted in decreased
MAGP2 expression and CD34+ microvessel
density in tumors developed in mice. Scale bars
represent 50 mm.
(D) A section of a high-grade serous adenocarci-
noma showing strong MAGP2 expression in tumor
cells (T) but not in the stromal component (S) or the
endothelial cells (arrowheads). The scale bar
represents 100 mm.
(E) Immunolocalization of CD34+ microvessels in
a human serous ovarian adenocarcinoma tumor
section.
(F) MAGP2 expression in a late-stage high-grade
human serous ovarian adenocarcinoma tumor
section.
(G) Correlation between CD34+ and MAGP2
expression.
2005; Wamunyokoli et al., 2006). These
signatures have been correlated with
histology, grade, and stage (Berchuck
et al., 2005; Bonome et al., 2005; Wa-
munyokoli et al., 2006). However, only a few methods have
been proposed to analyze survival outcome using microarray
data. The first approach uses unsupervised hierarchical clus-
tering followed by an assessment of survival distributions
among clusters using traditional approaches, e.g., log rank
test; however, our samples were all of the same histological
subtype (Sorlie et al., 2001). Furthermore, subgroups in this
cancer type have not been reported precluding use of a
cluster-based strategy. The second genre of analysis reduces
data dimensionality by clustering gene expression including
partial least-squares or support vector machines (Nguyen and
Rocke, 2002). These methods use a combination of all the
genes to predict survival by adding noise to the model, since
the vast majority of the genes should be unrelated to survival.
Indeed, studies have shown that using only a subset of genes
generally performs better than using all genes (Bair and Tibshir-
ani, 2004). Recent work by Berchuck et al. (2005), as well as
other groups, has used this type of approach to identify genes
associated with long-term survival in serous ovarian cancer
(Lancaster et al., 2004; Spentzos et al., 2004). However, it
remains unclear whether these predictors are applicable to
the majority of patients who will eventually die at an interme-
diate time point. In addition, their algorithms did not account
for censoring age and/or debulking status and were derived
from undissected isolates containing intervening stroma-
associated cells.528 Cancer Cell 16, 521–532, December 8, 2009 ª2009 Elsevier Inc.
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proportional hazards model evaluating survival as a continuous
variable relative to gene expression for a cohort of serous epithe-
lial cell tumor isolates (Cox, 1972). This statistical method incor-
porated censoring age and debulking variables returning
a hazard ratio measuring each gene’s effect on survival, rather
than scoring a multigene classifier. In this way, top survival-asso-
ciated genes were easily selected for PC analysis and evaluated
as a complex multigene predictor applicable to a broad range of
survival endpoints.
Despite clear delineation and validation of the 200 probe set
classifier, the broad range of genes that were identified
precluded unaided identification of coregulated signaling
pathways. By using pathway analysis software, we identified
aVb3 activation as a prominent survival-associated event. On
the basis of the expression data, the pathway was activated on
average across the panel of tumors that were evaluated versus
OSE, including a number of survival-associated genes. How-
ever, in patients surviving less than 1 year, there was a pro-
nounced overexpression of multiple prognostic genes, as
compared with individuals surviving beyond 5 years. This implies
that these genes may function as critical regulators suitable for
further evaluation as therapeutic targets.
Motivated by these findings, we used the data to characterize
the top survival-associated signature gene MAGP2. This
approach not only provided a biological validation of the prog-
nostic list but also demonstrated a link between protein expres-
sion and a number of tumor-associated processes. MAGP2 is
a 25 kDa matrix glycoprotein, which was originally identified by
its coextraction from developing fetal nuchal ligament tissue
(Gibson et al., 1996, 1989). The C-terminal half of MAGP2 inter-
acts with fibrillin-1 and -2, as well as fibulin-1, another compo-
nent of elastic fibers, suggesting that MAGP2 is an important
component in the assembly of microfibrils (Penner et al., 2002).
The N-terminal half of MAGP2 contains an RGD motif that has
been shown to mediate adhesion and spreading of fetal bovine
aortic smooth-muscle cells, ear cartilage chondrocytes, human
skin fibroblasts, and osteoblasts through the aVb3 integrin
receptor (Gibson et al., 1999). However, it has never been
identified or evaluated in the context of ovarian cancer.
Increased MAGP2 copy number supports the notion that
MAGP2 may play a causative role in the development of the
disease, and qRT-PCR and IHC both validated its prognostic
value. Interestingly, MAGP2 levels were also associated with
chemosensitivity. There is evidence that aVb3 signaling may
contribute to chemoresistance in ovarian cancer (Maubant
et al., 2002). In addition, chromosomal instability has been linked
to poor response to therapy (Salisbury et al., 2004). Survival-
associated NEDD9, which acts downstream of the aVb3 integrin
receptor, can activate both STK6/Aurora-A and NEK2, possibly
leading to aberrant chromosomal separation (Pugacheva and
Golemis, 2005). This suggests a mechanism whereby MAGP2
may be stimulating chemoresistance through a second prog-
nostic gene.
Beyond its clinical correlation, pathway analysis also sug-
gested a role for MAGP2 in ovarian tumor cell survival and endo-
thelial motility and survival. Indeed, treatment of both cell types
with recombinant and secreted supernatant proteins substanti-
ated these hypotheses. In endothelial cells, dissolution of tightCjunctions was evidenced by downregulation of PDK1, CLDN5,
and JAM3. These events may ultimately lead to decreased
vessel integrity and enhanced endothelial cell motility (Ebnet
et al., 2003; Kim et al., 2000; Morita et al., 1999). Increased
FAK phosphorylation, as well as calcium oscillation, also
supports the notion that MAGP2 can actuate aVb3 integrin
receptor signaling and promote motility.
Finally, correlation of MAGP2 expression with microvessel
density provided an in vivo indication that the cell line data is
of clinical relevance. This raises the potential that MAGP2 is
a proangiogenic factor in ovarian cancer. In addition, localization
to the extracellular matrix makes it an attractive target for thera-
peutic intervention. Without sufficient blood supply, tumor
expansion is severely limited. Furthermore, targeting a factor
affecting an endothelial cell with presumed genetic stability
may increase response. Ultimately, the development and expan-
sion of serous ovarian cancer involves a host of complex biolog-
ical processes. Nevertheless, this work identified at number of
prognostic genes and a coregulated regulated pathway that
may directly contribute to patient outcome. Among these genes,
MAGP2 featured prominently as a mediator of survival. Subse-
quent analyses will be necessary to confirm its proangiogenic
role as well as to assess the contribution of other survival-asso-
ciated genes.
EXPERIMENTAL PROCEDURES
Tissue Samples
A total of 53 snap-frozen tissue specimens and a validation set of 64 paraffin-
embedded tumor samples were obtained from previously untreated ovarian
cancer patients, who were hospitalized at the Brigham and Women’s Hospital
between 1990 and 2000. All patients had advanced stage, high-grade serous
ovarian cancer according to the International Federation of Gynecology and
Obstetrics standards. All specimens and their corresponding clinical informa-
tion were collected under protocols approved by the institutional review
boards of the corresponding institutions (for details, see tumor specimens
section in Supplemental Experimental Procedures) and informed consent
was obtained from all subjects.
Microdissection, Total RNA Extraction, Affymetrix GeneChip
Hybridization, and Image Acquisition
RNA was isolated and amplified from microdissected specimens as described
previously (Bonome et al., 2005). Hybridization, processing, and image acqui-
sition was done as described previously (Bonome et al., 2005).
To demonstrate that pure populations of epithelial cells were obtained, we
checked our arrays for the expression of endothelial cell markers (TIE-2 and
VEGFR2) and T cell markers (CD8 and CD45). None of the markers we exam-
ined were expressed on our arrays (see Figure S4).
Microarray Survival Analysis
Low-level analysis included array normalization and estimation of expression
level using an invariant set of probe sets to adjust the overall signal level of
the arrays to the same level (Sorlie et al., 2001). Next, a model-based PM-only
approach established gene expression levels using dChip software (Li and
Wong, 2001).
A modified ‘‘semi-supervised’’ method was applied (Bair and Tibshirani,
2004) in two stages: (1) Supervised dimension reduction was done by fitting
a univariate Cox model that included a jackknifing step to each gene, so
only those genes with a consistently large Cox score were included in the
signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized
predictor. (2) In stage 2, the dimensions of the data set were reduced from 200
to 5 by PC analysis. The number of PCs was set at five, capturing 90% of the
expression data. Four or six PCs were investigated to see whether this param-
eter affected the results. A prediction model was then built using multivariateancer Cell 16, 521–532, December 8, 2009 ª2009 Elsevier Inc. 529
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debulking status.
Standard leave-one-out validation evaluated the prediction model reserving
one sample for testing and using the remaining 52 patients to establish the
prediction model following the method described above. The reserved patient
had no contribution to the prediction model, yielding 53 separate predicted
hazards. Patients were equally divided into low- and high-risk groups accord-
ing to whether their hazard was less or greater than the sample median and
were compared by Kaplan Meier analysis with a nonparametric log rank test.
Microarray Pathway Analysis
The dChip PM-only algorithm was applied to the normal OSE and HUVEC line
data. Biometric Research Branch ArrayTools version 3.2.2 software developed
by R. Simon and A. Peng Lam of the Biometrics Research Branch of the
National Cancer Institute was used to filter and complete the statistical
analysis. Only those probe sets present in greater than 50% of the arrays
and displaying a variance in the top 50th percentile were evaluated.
Differentially expressed genes were identified for tumor and OSE specimens
using a multivariate permutation t test (p < 0.001). A total of 2000 permutations
were completed to identify a list of probe sets containing fewer than 5% false
positives at a confidence interval of 90%. For the HUVEC isolates, differentially
regulated genes were identified by a univariate t test (p < 0.01 and fold change
>1.5). A random-variance model was selected to permit information sharing
among probe sets.
Coregulated pathways underlying the survival-associated gene expression
signature and HUVEC signaling were analyzed using PathwayStudio version
4.0 software (Ariadne Genomics).
qPCR Analyses
Real-time PCR was performed as previously described (Wamunyokoli et al.,
2006). To calculate the relative expression for each gene, we used the
2-DDCT method to average the CT values for the three housekeeping genes
for a single reference gene value (Livak and Schmittgen, 2001).
Comparative Genome Hybridization and qPCR Validation
DNA from tumor cells from 42 of the late-stage, high-grade serous adenocar-
cinomas evaluated by microarray gene expression analysis were analyzed for
copy number alterations as previously described (Birrer et al., 2007). qPCR
validation of MAGP2 copy number was completed as previously described
(Birrer et al., 2007).
MAGP2 Survival and Chemoresponse Immunohistochemical
Analyses
The 53 stage III/IV grade 3 serous cases evaluated by gene expression
analysis, five normal ovaries, and five serous cystadenoma cases were
used. Immunolocalization and quantification of MAGP2 was performed using
a polyclonal anti-MAGP2 antibody at a dilution of 1:1000 and the ImagePro
Plus 5.1 software (Media Cybermetics) was used as previously described
(Birrer et al., 2007). The results were compared with matched survival data
and examined by Kaplan Meier survival analysis. Statistical significance was
determined by log rank test.
An independent validation set of 64 advanced stage high-grade papillary
serous tumors comprising a TMA were quantified for MAGP2 expression using
the antibody, instrumentation, and scoring method described above. Protein
expression levels were compared to overall survival by multivariate Cox
regression analysis adjusting for debulking status. p < 0.05 was considered
significant.
Synthesis of Recombinant and Mutant MAGP2 Constructs
Full-length human MAGP2 cDNA was amplified from Image Clone 377692
(primers in Supplemental Experimental Procedures) and cloned into the
EcoRI/NotI sites of yeast vector pPICZa(A) of the EasySelect Pichia expression
kit according to the manufacturer’s protocol (Invitrogen). For large-scale
growth, individual clones were induced with 0.5% methanol in BMMY media.
Recombinant protein in the supernatant was purified with the Ni+-NTA purifica-
tion system (Invitrogen) under native binding conditions. Isolation of re-
cMAGP2 was verified by western blotting after elution in 250 mM imidazole
and was quantified by silver staining (Invitrogen).530 Cancer Cell 16, 521–532, December 8, 2009 ª2009 Elsevier Inc.MAGP2 RGD motif mutants were constructed using the GeneEditor in vitro
site-directed mutagenesis system (Promega), according to the manufacturer’s
protocol. Three mutants were synthesized, including RGD/RAA, RGD/
TGD, and RGD/RGE (primers in Supplemental Experimental Procedures).
pcDna3.1():MAGP2 was used as the template.
Cell Lines and Culture Conditions
Human ovarian adenocarcinoma cell lines A224, OVCAR3, SKOV3, and
UCI107, OVCA429, and 293T cells were grown in RPMI-1640 or DMEM,
supplemented with 10% FBS, 2 mM glutamine, and penicillin/streptomycin
(Invitrogen). HUVECs (Cambrex) were grown in EBM supplemented with 2%
FBS and EGM-2 MV SingleQuots (Cambrex). All cells were maintained in
exponential growth phase at 37C in 5% CO2.
Western Blot Analysis
Protein lysates from ovarian cancer and OSE cultures were separated on 4%–
12% SDS gels (Amersham Biosciences) and incubated with an anti-MAGP2
antibody (Rockland Inc.). For assessing FAK phosphorylation in HUVECs, cells
were plated on 60 mm2 dishes and treated with 100 ng/ml recMAGP2 protein
for 30 min or with elute buffer control. For testing Ca2+ dependence, 50 mM of
the calcium signal blocking reagent BAPTA/AM (Molecular Probes) was added
to the HUVECs for 30 min before treatment with recMAGP2. Western blotting
was then performed on cell lysates under denaturing conditions on a 4%–20%
NuPAGE Tris-Glycine gel with a 1:1000 dilution of anti-FAK[pY397] mouse
monoclonal primary antibody (BD Biosciences) followed by a 1:20,000 dilution
of goat anti-mouse HRP-conjugated secondary antibody (Amersham Biosci-
ences). Bands were detected via ECL (Amersham Biosciences).
Flow Cytometry
Flow cytometry analysis was performed with anti-aVb3 integrin (23C6) FITC
conjugate and negative control IgG1 FITC conjugate (Santa Cruz Biotech-
nology). Cells were analyzed on a FACSAria Cell Sorting System (BD Biosci-
ences).
In Vitro Cell Line Assays
A224, UCI107, and HUVEC adhesion was assayed in 96-well plates were
treated with 30 ml recMAGP2 at the desired concentration for 18 hr at 4C.
The cells were suspended in serum-free media (1 mg/ml BSA) and plated in
quadruplicate in the pretreated 96-well plates and observed every 5 min.
Once adhesion/spreading was observed in treated wells, the plate was shaken
for 30 s on an automatic plate shaker to remove unattached cells. The medium
was removed, washed once with PBS, and replaced with fresh medium. Cell
number was determined by MTT (Promega). Blocking of adhesion was
performed by treating cells with antibody for 30 min in serum-free media
with 1 mg/ml BSA before plating [anti-integrin aVb3 (LM609) and IgG1
(MABC002) (Chemicon)].
For HUVEC motility assays, cells were plated in triplicate in 350 ml in the
upper chamber of a 8.0 mM pore size PET membrane 24-well cell culture insert
(BD Biosciences). The bottom chamber contained 500 ml of 0.2% FBS media
with 100 ng/ml recMAGP2 as a chemoattractant. After cells attached for 3 hr,
the insert was removed and the cells on the underside were fixed and stained
with Diff-Quick Stain Set (Dade Behring). Cell number was quantified by count-
ing five 2003 fields of view per membrane.
Blocking of motility was performed as above, with a 30 min antibody
pretreatment using anti-aVb3 integrin (LM609), anti-a5 integrin (IIA1), anti-b1
integrin (4B4) (BD Biosciences), or IgG1 (MABC002) antibodies.
HUVEC motility was also assessed using supernatant from 293T or UCI107
cells transfected with pcDNA3.1():MAGP2 or RGD motif mutants. Each cell
line was plated in 100 mm2 dishes O/N in DMEM or RPMI, respectively, trans-
fected with 3 mg DNA O/N, and cultured in new media containing 0.2% EBM for
36 hr.
For HUVEC invasion, inserts were pretreated with 100 ml Matrigel (BD
Biosciences) at 0.5 mg/ml in the dark for 18 hr at RT. The bottom chamber
contained 200 ng/ml recMAGP-2. Cells were allowed to invade for 24 hr before
staining.
HUVEC survival was evaluated by plating cells in quadruplicate in 96-well
plates at 25% confluence in 100 ml of 0.2% EBM. recMAGP2 was added on
day 0 and 2 at 50 ng/ml. Cell number was quantified by MTT on day 5.
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The effect of recMAGP2 on [Ca2+]i of cultured ovarian HUVECs were monitored
with confocal fluorescence microscopy using Fluo-4/AM (a cell-permeable
calcium-sensitive fluorescence dye). Cultured cells on coverslips were loaded
with Fluo-4/AM (5 M) in phenol-red-free culture medium for 20 min, washed,
and incubated for another 20 min for deesterification. Coverslips were then
positioned in a temperature-controlled perfusion chamber mounted on a Zeiss
inverted microscope. Confocal fluorescence images were collected with a
Bio-Rad MRC-1000 confocal scanning unit at 0.5 HZ through a 403 objective
(NA 1.2). recMAGP2 (100 ng/ml) was introduced into the perfusion chamber
through the inlet port. Changes in emission intensity of Fluo-4 from individual
cell induced by recMAGP2 were measured retrospectively from each image.
In Vivo Studies
Ovarian cancer cells, SKOV3, were stably transfected with MAGP2 shRNA or
the vector. Five stable clones were selected for each group. For lentivirus
experiments, four different viral transduction particles were used: three
expressing shRNA targeting different regions of MAGP2 and one expressing
a nontargeting shRNA. SKOV3 and OVCAR 3 were transduction as per the
vendor’s instruction (Sigma-Aldrich). Pools of resistant clones were isolated.
The animal protocol is approved by the Institutional Animal Care and Use
Committee at the University of Texas M.D. Anderson Cancer Center. A total
of 5 3 105 cells from each clone or pool were injected subcutaneously into
the posterior neck region of five nude mice (6- to 8-week-old female nude
mice; Charles River). After 4 weeks, the mice were sacrificed and the tumors
developed from each mouse were removed and weighed. The clones were
subsequently fixed in formalin and processed for histological evaluation.
MAGP2 expression in tumor tissues was evaluated using a rabbit anti-human
MAGP-2 antibody (Rockland Inc.) and the microvessel density was deter-
mined by immunolocalization of CD34+ blood vessels using a goat anti-mouse
polyclonal antibody. Significant differences in the weight of the tumors
between the MAGP2 shRNA and the control group were determined by
Mann-Whitney U test. A p-value < 0.05 was considered significant.
Evaluation of CD34+ Microvessel Density
Immunolocalization of CD34+ endothelial cells was performed on 30 of the
tumors included in the microarray analysis using formalin-fixed paraffin-
embedded tissue with a commercially available anti-CD34 monoclonal anti-
body (Dako Cytomation) and the ABC system (Vector Laboratories). Grading
of CD34-positive blood vessels was performed as previously described (Birrer
et al., 2007). A Spearmen’s rho tested the correlation between MAGP2 expres-
sion with CD34+ microvessel density.
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